Although most solid tumors contain inactivating mutations of the p53 tumor suppressor, hematological malignancies do not contain frequent alterations in the p53 gene (<20%). How these tumors arise in the presence of a super tumor suppressor like p53 remains to be elucidated. Given the number of downstream effectors of p53, it is likely that critical targets of p53 are inactivated in leukemia, bypassing the requirement for p53 gene mutations in these tumors. This review describes new biochemical and transcriptional activities of p53 as well as the status of p53 in acute myelogenous leukemia and chronic myelogenous leukemia.

Keywords:
p53, Acute myeloid leukemia, Chronic myeloid leukemia, Myelodysplastic syndrome
1.
Asher G, Lotem J, Kama R, Sachs L, Shaul Y: Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci USA 2002;99:13125–13130.
2.
Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K: Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997;89:1175–1184.
3.
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674–1677.
4.
Banker DE, Radich J, Becker A, Kerkof K, Norwood T, Willman C, Appelbaum FR: The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 1998;4:3051–3062.
5.
Beitel LK, Elhaji YA, Lumbroso R, Wing SS, Panet-Raymond V, Gottlieb B, Pinsky L, Trifiro MA: Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J Mol Endocrinol 2002;29:41–60.
6.
Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677–1679.
7.
Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999;96:13777–13782.
8.
Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001;19:1405–1413.
9.
De Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982;300:765–767.
10.
Dimartino JF, Cleary ML: Mll rearrangements in haematological malignancies: Lessons from clinical and biological studies. Br J Haematol 1999;106:614–626.
11.
Downing JR: The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: Biology and clinical significance. Br J Haematol 1999;106:296–308.
12.
El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817–825.
13.
Felix CA: Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233–255.
14.
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T: p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560–564.
15.
Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003;3:117–130.
16.
Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z: MDM2 association with p53 targets its ubiquitination. Oncogene 1998;17:2543–2547.
17.
Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE: Requirement for MDM2 in the survival effects of BCR-ABL and interleukin-3 in hematopoietic cells. Cancer Res 2001;61:7635–7641.
18.
Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM: Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003;300:342–344.
19.
Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595–606.
20.
Hartmann-Petersen R, Seeger M, Gordon C: Transferring substrates to the 26S proteasome. Trends Biochem Sci 2003;28:26–31.
21.
Haupt Y, Maya R, Kazaz A, Oren M: MDM2 promotes the rapid degradation of p53. Nature 1997;387:296–299.
22.
Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3–11.
23.
Hofmann WK, Takeuchi S, Xiw D, Miller CW, Hoelzer D, Koeffler HP: Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes. Leuk Res 2001;25:855–858.
24.
Honda H, Oda H, Suzuki T, Takahashi T, Witte ON, Ozawa K, Ishikawa T, Yazaki Y, Hirai H: Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-positive leukemias. Blood 1998;91:2067–2075.
25.
Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa S, Ishikawa T, Yazaki Y, Hirai H: Acquired loss of p53 induces blastic transformation in p210 (bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML. Blood 2000;95:1144–1150.
26.
Horiike S, Misawa S, Kaneko H, Sasai Y, Kobayashi M, Fujii H, Tanaka S, Yagita M, Abe T, Kashima K, Taniwaki M: Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 1999;13:1235–1242.
27.
Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E, Koeffler HP: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113–1120.
28.
Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C et al: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994;13:1073–1083.
29.
Krug U, Ganser A, Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002;21:3475–3495.
30.
Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by MDM2. Regulation of p53 stability by MDM2. Nature 1997;387:299–303.
31.
Kubbutat MH, Vousden KH: Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol Cell Biol 1997;17:460–468.
32.
Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P: Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995;9:370–381.
33.
Lanza C, Gaidano G, Cimino G, Pastore C, Nomdedeu J, Volpe G, Vivenza C, Parvis G, Mazza U, Basso G, Madon E, Lo Coco F, Saglio G: Distribution of TP53 mutations among acute leukemias with MLL rearrangements. Genes Chromosomes Cancer 1996;15:48–53.
34.
Laronga C, Yang HY, Neal C, Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000;275:23106–23112.
35.
Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S: Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779–791.
36.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998;396:643–649.
37.
Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM: Binding and modulation of p53 by p300/CBP coactivators. Nature 1997;387:823–827.
38.
Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW: The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002;8:743–750.
39.
Maki K, Mitani K, Yamagata T, Kurokawa M, Kanda Y, Yazaki Y, Hirai H: Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia. Blood 1999;93:3216–3224.
40.
Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM: p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003;11:577–590.
41.
Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP: Human p53 gene localized to short arm of chromosome 17. Nature 1986;319:783–784.
42.
Mitani K, Kanda Y, Ogawa S, Tanaka T, Inazawa J, Yazaki Y, Hirai H: Cloning of several species of MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation. Blood 1995;85:2017–2024.
43.
Mori N, Morosetti R, Spira S, Lee S, Ben-Yehuda D, Schiller G, Landolf R, Mizoguchi H, Koeffler HP: Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelogenous leukemia. Blood 1998;92:3405–3409.
44.
Nakai H, Misawa S, Horiike S, Maekawa T, Kashima K, Ishizaki K: Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia. Br J Haematol 1995;90:147–155.
45.
Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K, Ishii E, Zannini L, Delia D, Mizutani S: Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood 2003;101:3622–3627.
46.
Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG: PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000;406:207–210.
47.
Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991;66:161–171.
48.
Pierce A, Spooncer E, Wooley S, Dive C, Francis JM, Miyan J, Owen-Lynch PJ, Dexter TM, Whetton AD: BCR-ABL protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. Oncogene 2000;19:5487–5497.
49.
Poirel H, Rack K, Delabesse E, Radford-Weiss I, Troussard X, Debert C, Leboeuf D, Bastard C, Picard F, Veil-Buzyn A, Flandrin G, Bernard O, Macintyre E: Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 1996;87:2496–2505.
50.
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 1998;92:713–723.
51.
Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983;3:2143–2150.
52.
Rowley JD, Testa JR: Chromosome abnormalities in malignant hematologic diseases. Adv Cancer Res 1982;36:103–148.
53.
Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB: Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia 1998;12:840–844.
54.
Simpson L, Parsons R: PTEN: Life as a tumor suppressor. Exp Cell Res 2001;264:29–41.
55.
Sionov RV, Coen S, Goldberg Z, Berger M, Bercovich B, Ben-Neriah Y, Ciechanover A, Haupt Y: c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 2001;21:5869–5878.
56.
Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Calabretta B: Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc Natl Acad Sci USA 1996;93:13137–13142.
57.
Stilgenbauer S, Dohner H: Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452–453.
58.
Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R, Sandberg AA et al: Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993;329:909–914.
59.
Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152–157.
60.
Vousden KH, Lu X: Live or let die: The cell’s response to p53. Nat Rev Cancer 2002;2:594–604.
61.
Wahl GM, Carr AM: The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat Cell Biol 2001;3:E277–E286.
62.
Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ, Kelly K: Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature 1994;367:651–654.
63.
Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158–3165.
64.
Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC: PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 2003;422:527–531.
65.
Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725–734.
© 2004 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.